Style | Citing Format |
---|---|
MLA | Moghadam ES, et al.. "Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide." Medicinal Chemistry, vol. 16, no. 3, 2020, pp. 340-349. |
APA | Moghadam ES, Saravani F, Hamel E, Shahsavari Z, Alipour M, Hosseinkhani S, Ostad S, Amini M (2020). Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide. Medicinal Chemistry, 16(3), 340-349. |
Chicago | Moghadam ES, Saravani F, Hamel E, Shahsavari Z, Alipour M, Hosseinkhani S, Ostad S, Amini M. "Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide." Medicinal Chemistry 16, no. 3 (2020): 340-349. |
Harvard | Moghadam ES et al. (2020) 'Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide', Medicinal Chemistry, 16(3), pp. 340-349. |
Vancouver | Moghadam ES, Saravani F, Hamel E, Shahsavari Z, Alipour M, Hosseinkhani S, et al.. Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide. Medicinal Chemistry. 2020;16(3):340-349. |
BibTex | @article{ author = {Moghadam ES and Saravani F and Hamel E and Shahsavari Z and Alipour M and Hosseinkhani S and Ostad S and Amini M}, title = {Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide}, journal = {Medicinal Chemistry}, volume = {16}, number = {3}, pages = {340-349}, year = {2020} } |
RIS | TY - JOUR AU - Moghadam ES AU - Saravani F AU - Hamel E AU - Shahsavari Z AU - Alipour M AU - Hosseinkhani S AU - Ostad S AU - Amini M TI - Design, Synthesis and In-Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-Diaryl-1H-Pyrrol-3-Yl)-2-Oxo-N-(Pyridin-3-Yl)Acetamide JO - Medicinal Chemistry VL - 16 IS - 3 SP - 340 EP - 349 PY - 2020 ER - |